KMT2A and acute myeloid leukemia: ORY-1001 has been reported to induce expression of differentiation markers in mixed lineage leukemia (MLL) cells as well as reducing tumor growth in an acute myeloid leukemia (AML) mouse model and possesses good oral bioavailability (Harris et al., 2012; Maes et al., 2013, 2015).